Nirsevimab: Alleviating the burden of RSV morbidity in young children

• Published in: Journal of paediatrics and child health 2024-10, Vol.60 (10), p.489-498
• Main Authors: Loe, Marcus Wing Choy, Soenong, Helen, Lee, Evelyn, Li‐Kim‐Moy, Jean, Williams, Phoebe CM, Yeo, Kee Thai
• Format: Article
• Language: English
• Subjects: child; cost‐effectiveness analysis; Immunotherapy; Monoclonal antibodies; newborn infant; nirsevimab; Pediatrics; Respiratory syncytial virus; respiratory syncytial virus infections
• ISSN: 1034-4810; 1440-1754; 1440-1754
• DOI: 10.1111/jpc.16643

Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory tract infections (LRTIs) and hospital admissions in early childhood. Recent advancements in novel preventive therapies, including extended half‐life monoclonal antibodies and antenatal vaccination, have afforded new opportunities to significantly reduce the burden of this infection. Nirsevimab is a novel monoclonal antibody that provides sustained protection against RSV for at least 5 months among newborns and young children. It has received regulatory approval in numerous countries and is being implemented across various settings. Two pivotal Phase 3 trials (MELODY, HARMONIE) demonstrated significant reductions in RSV‐associated LRTI hospitalisations following nirsevimab administration, with treatment efficacy of 62.1% and 83.2%. Emerging real‐world data from early adopters of nirsevimab corroborates these findings. Studies from Spain, Luxembourg, France and the USA report effectiveness rates between 82% and 90% in preventing RSV‐associated hospitalisations among infants entering their first RSV season. Current implementation strategies for nirsevimab have primarily focused on seasonal administration for all infants, aligned to local RSV seasons, and often include catch‐up doses for those born before the season begins. Available cost‐effectiveness analyses indicate that while nirsevimab offers significant potential public health benefits, its adoption must carefully consider economic factors such as treatment costs, implementation strategies tailored to local viral epidemiology, and logistics for vaccine delivery. Overall, nirsevimab presents a promising opportunity to alleviate the burden of severe RSV infections in young children. However, ongoing surveillance and refinements in implementation strategies are crucial to optimise its impact and ensure sustainability across diverse health‐care settings.